You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
Dow
Boehringer Ingelheim
Johnson and Johnson
Mallinckrodt
Merck

Last Updated: July 11, 2020

DrugPatentWatch Database Preview

Patent: 8,815,879

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,815,879
Title:Substituted 4-(selenophen-2(or-3)-ylamino)pyrimidine compounds and methods of use thereof
Abstract: Selenophene compounds of formula (I) are described herein. In the compounds of Formula (I), ring A is a 6-membered aromatic fused ring, optionally containing one, two or three nitrogen atoms; a 5-membered heteroaromatic fused ring; or a mono- or bicyclic saturated heterocyclic fused ring having at least one ring member selected from the group consisting of N, O, S, SO and SO.sub.2; Y in ring B is nitrogen or substituted carbon; X is NR.sup.6, O, S, S(O), or S(O).sub.2. R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.6 are defined in the specification. Selenophene compounds of formula (I) may be used in methods of treating cell proliferative disorders, particularly cancer. Pharmaceutical compositions containing selenophene compounds of formula (I) may be used for treatment, inhibition, or control of cancer. ##STR00001##
Inventor(s): Kasina; Sudhakar (Mercer Island, WA), Gokaraju; Ganga Raju (Vijayawada, IN), Somepalli; Venkateswarlu (Vijayawada, IN), Gokaraju; Rama Raju (Vijayawada, IN), Gokaraju; Venkata Kanaka Ranga Raju (Vijayawada, IN), Bhupathiraju; Kiran (Vijayawada, IN), Golakoti; Trimurtulu (Vijayawada, IN), Sengupta; Krishanu (Vijayawada, IN), Alluri; Venkata Krishna Raju (Vijayawada, IN)
Assignee: Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN)
Application Number:13/896,538
Patent Claims:see list of patent claims

Details for Patent 8,815,879

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2030-11-18 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2030-11-18 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2030-11-18 RX Orphan search
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08   Start Trial Kasina Laila Innova Pharmaceuticals Private Limited (Vijayawada, IN) 2030-11-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Colorcon
Medtronic
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.